Publications by authors named "Craig T Morita"

Background: Shared decision-making (SDM) is a principle of humanistic, patient-centered health care within the field of rheumatology. However, clear communication between patients and their clinicians regarding the benefits and risks of immunomodulators may be challenging in a clinical setting. The design-thinking process is a human-centered approach to quality improvement that can help to identify insights to uphold high-quality communication.

View Article and Find Full Text PDF

Cholangiocarcinoma (CCA) is a rare disease characterized by malignant cells derived from the epithelial cells of the biliary duct system. Despite extensive treatments, the prognosis for CCA remains poor, emphasizing the critical need for the development of novel treatments. Considerable attention has been directed towards innate immune effector cells, which can recognize tumor cells independently of the major histocompatibility complex, laying the foundation for the development of off-the-shelf drugs.

View Article and Find Full Text PDF

Human Vγ2Vδ2 (also termed Vγ9Vδ2) T cells play important roles in microbial and tumor immunity by monitoring foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis. Accumulation of isoprenoid metabolites after bisphosphonate treatment allows Vγ2Vδ2 T cells to recognize and kill tumors independently of their MHC expression or burden of non-synonymous mutations. Clinical trials with more than 400 patients show that adoptive immunotherapy with Vγ2Vδ2 T cells has few side effects but has resulted in only a few partial and complete remissions.

View Article and Find Full Text PDF
Article Synopsis
  • Research highlights the potential of γδ T cells, specifically those with Vγ2Vδ2 receptors, in cancer immunotherapy, showing promise for expansion and effectiveness via a novel bisphosphonate prodrug called PTA.
  • PTA was found to enhance the accumulation of key metabolites that stimulate Vγ2Vδ2 T cell activation, allowing for increased purity and effectiveness in targeting cancer cells.
  • The study demonstrated that Vγ2Vδ2 T cells require more time and cell numbers for effective tumor lysis when targeting lung cancer cells directly, but can rapidly induce cytotoxicity when cancer cells are sensitized with PTA, offering insights for optimizing therapeutic strategies.
View Article and Find Full Text PDF

Vγ2Vδ2 T cells play important roles in human immunity to pathogens and tumors. Their TCRs respond to the sensing of isoprenoid metabolites, such as ()-4-hydroxy-3-methyl-but-2-enyl pyrophosphate and isopentenyl pyrophosphate, by butyrophilin (BTN) 3A1. BTN3A1 is an Ig superfamily protein with extracellular IgV/IgC domains and intracellular B30.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on improving methods to measure cellular cytotoxicity of immune effector cells, which are important for cancer treatment through adoptive transfer.
  • Researchers developed a non-radioactive assay using a prodrug (BM-HT) combined with europium (Eu) to assess the effectiveness of γδ T cells and compared it with terbium (Tb).
  • Results indicated that the Tb-based detection system is more sensitive than the Eu system, which could enhance future cell therapies for cancer by providing better measurement techniques.
View Article and Find Full Text PDF

Immune checkpoint blockade using anti-PD-1/PD-L1 or anti-CTLA-4 monoclonal antibodies (mAbs) has revolutionized cancer treatment. However, many types of cancer do not respond and for those that do, only a minority of patients achieve durable remissions. Therefore, oncoimmunologists are working to develop adoptive cell therapies for non-hematopoietic tumors by harnessing immune effector cells such as αβ T cells and γδ T cells.

View Article and Find Full Text PDF
Article Synopsis
  • Cancer immunotherapy utilizing Vγ2Vδ2 T cells shows promise for targeting tumors without needing to match MHC, making it effective across various cancer types.
  • A novel method using a bisphosphonate prodrug called PTA has been developed to significantly increase the purity and quantity of these T cells, achieving up to 99% purity versus lower rates with the standard agent, zoledronic acid.
  • This enhanced purity improves success rates for engrafting these T cells into immunocompromised mice and could expedite the creation of therapies using T cells from HLA-matched donors for patients who do not respond well to their own immune cell treatments.
View Article and Find Full Text PDF

Immunotherapy using immune checkpoint inhibitors and CAR-T cells has revolutionized treatment for patients with malignant tumors. However, measuring tumor cell cytotoxicity mediated by immune effector cells in clinical laboratories has been difficult due to the requirement for radioactive substances. In this study, a series of novel terpyridine derivative proligands were synthesized, and a non-radioactive cellular cytotoxicity assay using the newly synthesized compounds was developed for use in preclinical and clinical studies for cancer immunotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Bisphosphonates have been used in treating breast cancer and multiple myeloma, working alongside γδ T cell immunotherapy, but traditional bisphosphonates have limited effectiveness and cause bone-related side effects.* -
  • Researchers developed bisphosphonate prodrugs, which enter cancer cells and convert to active forms that more effectively stimulate γδ T cells to attack tumors compared to standard treatments.* -
  • In preclinical models, a specific prodrug enhanced the effectiveness of γδ T cell therapy, leading to improved survival rates in mice with tumors, suggesting a promising new combination approach for cancer treatment.*
View Article and Find Full Text PDF

Background: Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with Vγ2Vδ2 T cells has been used to treat cancer patients with partial and complete remissions. Most clinical trials and preclinical studies have used continuous zoledronate exposure to expand Vγ2Vδ2 cells where zoledronate is slowly diluted over the course of the culture.

View Article and Find Full Text PDF
Article Synopsis
  • Nitrogen-containing bisphosphonates show some antitumor activity in breast cancer and myeloma patients but have limited efficacy and cause bone-related side effects.
  • New heterocyclic bisphosphonate prodrugs have been developed to enhance absorption and effectiveness by masking negative charges, allowing for better entry into tumor cells.
  • The most effective prodrug, identified as compound 7, significantly inhibits tumor growth, particularly in hematopoietic cells, and outperforms the currently approved drug zoledronic acid in preclinical tests.
View Article and Find Full Text PDF

γδ T cells function at the interface between innate and adaptive immunity and have well-demonstrated roles in response to infection, autoimmunity and tumors. A common characteristic of these seemingly disparate conditions may be cellular stress or death. However, the conditions under which ligands for γδ T cells are induced or exposed remain largely undefined.

View Article and Find Full Text PDF

Vγ2Vδ2 T cells play important roles in human immunity to pathogens and in cancer immunotherapy by responding to isoprenoid metabolites, such as (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate and isopentenyl pyrophosphate. The Ig superfamily protein butyrophilin (BTN)3A1 was shown to be required for prenyl pyrophosphate stimulation. We proposed that the intracellular B30.

View Article and Find Full Text PDF

Human Vγ2Vδ2 T cells monitor isoprenoid metabolism by recognizing foreign (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), a metabolite in the 2-C-methyl-D-erythritol-4-phosphate pathway used by most eubacteria and apicomplexan parasites, and self isopentenyl pyrophosphate, a metabolite in the mevalonate pathway used by humans. Whereas microbial infections elicit prolonged expansion of memory Vγ2Vδ2 T cells, immunization with prenyl pyrophosphates or aminobisphosphonates elicit short-term Vγ2Vδ2 expansion with rapid anergy and deletion upon subsequent immunizations. We hypothesized that a live, attenuated bacterial vaccine that overproduces HMBPP would elicit long-lasting Vγ2Vδ2 T cell immunity by mimicking a natural infection.

View Article and Find Full Text PDF

Most human γδ T cells express Vγ2Vδ2 TCRs and play important roles in microbial and tumor immunity. Vγ2Vδ2 T cells are stimulated by self- and foreign prenyl pyrophosphate intermediates in isoprenoid synthesis. However, little is known about the molecular basis for this stimulation.

View Article and Find Full Text PDF

We synthesized 30 lipophilic bisphosphonates and tested them in malaria parasite killing (targeting parasite geranylgeranyl diphosphate synthase, GGPPS) as well in human γδ T cell activation (targeting human farnesyl diphosphate synthase, FPPS). Similar patterns of activity were seen in inhibiting human FPPS and GGPPS, with short to medium chain-length species having most activity. In cells, shorter chain-length species had low activity, due to poor membrane permeability, and longer chain length species were poor enzyme inhibitors.

View Article and Find Full Text PDF

Exposing human tumor cells to nitrogen-containing bisphosphonates, such as zoledronic acid (Zol), greatly increases their susceptibility to killing by γδ T cells. Based on this finding and other studies, cancer immunotherapy using γδ T cells and nitrogen-containing bisphosphonates has been studied in pilot clinical trials and has shown benefits. Although Zol treatment can render a wide variety of human tumor cells susceptible to γδ T cell killing, there has not been a systematic investigation to determine which types of tumor cells are the most susceptible to γδ T cell-mediated cytotoxicity.

View Article and Find Full Text PDF
Article Synopsis
  • Human γδ T cells show strong cancer-fighting capabilities when paired with zoledronic acid (Zol), especially in early-stage breast cancer and multiple myeloma treatments.
  • This study explored how Vγ2Vδ2 T cells from breast cancer patients react to Zol and the effects of IL-18 on their growth and responsiveness.
  • Findings reveal that while IL-18 boosts the activity of these T cells, Zol can lower their numbers and weaken their overall responsiveness in early-stage breast cancer patients.
View Article and Find Full Text PDF

HMBPP ((E)-4-hydroxy-3-methyl-2-butenyl pyrophosphate) is a highly potent innate immunogen that stimulates human γδ T cells expressing the Vγ2Vδ2 T cell antigen receptor. To determine if glycoside conjugates of HMBPP retain activity, the 4-β-glucoside and its acetylated homolog were synthesized and tested for their ability to stimulate γδ T cells. The glycoside HMBPP conjugate stimulated human γδ T cells with an EC(50) of 78nM.

View Article and Find Full Text PDF

Human Vγ2Vδ2 T cells monitor isoprenoid metabolism by recognizing (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), an intermediate in the 2-C-methyl-d-erythritol-4-phosphate pathway used by microbes, and isopentenyl pyrophosphate (IPP), an intermediate in the mevalonate pathway used by humans. Aminobisphosphonates and alkylamines indirectly stimulate Vγ2Vδ2 cells by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate pathway, thereby increasing IPP/triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester that directly stimulate. In this study, we further characterize stimulation by these compounds and define pathways used by new classes of compounds.

View Article and Find Full Text PDF

The regulation of IL-17A and IL-22 production differs between human and murine γδ T cells. We find that human γδ T cells expressing Vγ2Vδ2 T cell receptors are peripherally polarized to produce IL-17A or IL-22, much like CD4 αβ Th17 T cells. This requires IL-6, IL-1β, and TGF-β, whereas expansion and maintenance requires IL-23, IL-1β, and TGF-β.

View Article and Find Full Text PDF

Virulent varicella-zoster virus (VZV) can spread in immunocompetent humans, resulting in symptoms mostly of the skin. In contrast, vaccine Oka (V-Oka), the attenuated VZV vaccine strain, only rarely causes clinical reactions. The mechanisms underlying these pathogenetic differences are unclear.

View Article and Find Full Text PDF

gammadelta T cells differ from alphabeta T cells in the Ags they recognize and their functions in immunity. Although most alphabeta TCRs recognize peptides presented by MHC class I or II, human gammadelta T cells expressing Vgamma2Vdelta2 TCRs recognize nonpeptide prenyl pyrophosphates. To define the molecular basis for this recognition, the effect of mutations in the TCR CDR was assessed.

View Article and Find Full Text PDF

Human gammadelta T cells expressing the Vgamma2Vdelta2 TCR play important roles in immune responses to microbial pathogens by monitoring prenyl pyrophosphate isoprenoid metabolites. Most adult Vgamma2Vdelta2 cells are memory cytotoxic cells that produce IFN-gamma. Recently, murine gammadelta T cells were found to be major sources of IL-17A in antimicrobial and autoimmune responses.

View Article and Find Full Text PDF